{ "@context": "https://clearank.com/llms.txt", "@type": "clearank:AssetAnalysis", "url": "https://clearank.com/etf/ishares-biotechnology-ibb/", "dataUrl": "https://clearank.com/etf/ishares-biotechnology-ibb/data.json", "title": "iShares Biotechnology ETF (IBB) ETF Forecast (2026)", "description": "iShares Biotechnology (IBB) ETF: 0.44% expense ratio. $10.5B net assets. Health. iShares. Fund facts, AI rating, technicals and 2030 projection.", "headline": "iShares Biotechnology ETF (IBB)", "published": "2026-07-03T09:44:40+00:00", "modified": "2026-09-12T19:56:26.928+00:00", "generated": "2026-09-12T22:01:04.739Z", "language": "en-US", "publisher": { "name": "CleaRank", "url": "https://clearank.com/" }, "disclaimer": "Educational and informational only; not financial advice. AI-generated analysis reviewed by the CleaRank editorial team; prices delayed up to 15 minutes.", "asset": { "ticker": "IBB", "name": "iShares Biotechnology ETF", "type": "ETF", "exchange": "NASDAQ", "currency": "USD", "sector": null, "industry": null, "country": "United States", "website": null }, "quote": { "price": 202.93, "previousClose": 202.64, "change": 0.29, "changePercent": 0.14, "open": 203.94, "high": 205.31, "low": 202.75, "volume": 2286300, "averageVolume": 1526680, "marketCap": 11780694016, "fiftyTwoWeekHigh": 217.12, "fiftyTwoWeekLow": 137.64, "marketOpen": false, "asOf": "2026-09-12T19:56:26.000Z" }, "statistics": { "pe": 25.35191, "eps": null, "dividendYield": 0.0004686840949266668, "beta": null, "priceToSales": null, "priceToBook": null, "revenueTtm": 0, "grossMargin": null, "returnOnEquity": null }, "technicals": { "rsi": 31.46, "macd": 2.26, "sma50": 199.1, "sma200": 178.31, "rsiSignal": "Bearish", "trend": "Bullish", "pricePosition": "Bullish", "macdSignal": "Bullish", "rating": "Bullish" }, "analysis": { "rating": "Sell", "score": 35, "consensus": "Sell", "fairValue": null, "analystTarget": 186.7, "analystCount": null, "wallStreetConsensus": "", "generatedAt": "2026-09-12T19:56:26.000Z", "priceAtAnalysis": 202.92999, "volatility": { "daily": 1.78, "risk": "etf" } }, "tradePlan": { "bias": "Bearish", "conservativeEntry": 206.99, "aggressiveEntry": 202.93, "stopLoss": 213.2, "stopLossPercent": 3, "targets": [ 196.64, 186.29, 175.94 ] }, "projections": { "basis": "Monte Carlo simulation on historical return distribution, re-run daily; not price targets", "years": [ { "year": 2027, "downside10th": 162.01, "base": 218.16, "upside90th": 293.78 }, { "year": 2028, "downside10th": 153.97, "base": 234.54, "upside90th": 357.26 }, { "year": 2029, "downside10th": 150.59, "base": 252.14, "upside90th": 422.17 }, { "year": 2030, "downside10th": 149.48, "base": 271.06, "upside90th": 491.53 }, { "year": 2031, "downside10th": 149.8, "base": 291.41, "upside90th": 566.88 }, { "year": 2032, "downside10th": 151.13, "base": 313.28, "upside90th": 649.39 }, { "year": 2033, "downside10th": 153.26, "base": 336.8, "upside90th": 740.12 }, { "year": 2034, "downside10th": 156.05, "base": 362.07, "upside90th": 840.12 }, { "year": 2035, "downside10th": 159.41, "base": 389.25, "upside90th": 950.49 }, { "year": 2036, "downside10th": 163.29, "base": 418.47, "upside90th": 1072.39 } ] }, "faqCount": 7, "sources": [ "TwelveData", "Wall Street consensus" ], "sections": [ { "id": "price", "title": "IBB Price Analysis" }, { "id": "market-metrics", "title": "Market Metrics", "facts": { "Open": "$203.94", "Day Range": "$202.75 to $205.31", "Prev Close": "$202.64", "Volume": "2.29M", "52-Week Range": "$137.64 to $217.12", "Market Cap": "$11.78B" } }, { "id": "mi-fund-facts", "title": "IBB Fund Facts", "text": [ "iShares Biotechnology ETF is an exchange-traded fund that provides broad exposure to U.S.-listed biotechnology companies. The fund is designed to track a biotechnology-focused index and typically holds a diversified basket of large, mid, and smaller biotechnology names, along with select life sciences tools and services companies that support drug discovery and research. Its portfolio includes firms involved in areas such as therapeutics, genetic medicine, diagnostics, and advanced research platforms.", "Fund reference data as of Sep 12, 2026. Expense ratio and net assets are reported by the fund; returns are total returns and can differ from price change." ], "tables": [ { "caption": "", "columns": [ "Period", "IBB", "Category" ], "rows": [ { "label": "YTD", "cells": [ "23.98%", "-2.39%" ] }, { "label": "1 month", "cells": [ "12.11%", "1.70%" ] }, { "label": "3 months", "cells": [ "21.34%", "-3.03%" ] }, { "label": "1 year", "cells": [ "51.66%", "21.31%" ] }, { "label": "3 years", "cells": [ "17.87%", "6.58%" ] }, { "label": "5 years", "cells": [ "4.20%", "1.49%" ] }, { "label": "10 years", "cells": [ "8.63%", "8.56%" ] } ] } ] }, { "id": "analysis", "title": "IBB Analysis", "text": [ "IBB's nearest resistance is its 20-day EMA at $206.78, which it is currently trading below. The 50-day Simple Moving Average (SMA) at $199.10 acts as support, with the price currently above it. The 200-day SMA at $178.31 also provides a longer-term support level. The RSI is at 31.46, confirming a bearish momentum signal. The MACD is at 2.26, suggesting a potential shift towards bearishness. The Stochastic indicator is at 6.64, indicating oversold conditions in the short term.", "The iShares Biotechnology ETF (IBB) faces a mixed outlook. While its long-term performance has been strong, outperforming its category over multiple periods, current technical indicators suggest short-term weakness. The price is below the 20-day EMA, and the RSI is bearish. A break below the 50-day SMA at $199.10 could signal further downside. However, if the underlying biotechnology sector experiences a resurgence driven by innovation or positive regulatory news, IBB could regain upward momentum. The ETF's substantial net assets and diversified holdings within the biotech space provide a solid foundation for potential recovery." ], "lists": { "ProTips": [ "Monitor the 20-day EMA ($206.78) as a key short-term resistance level.", "Watch for a potential test of the 50-day SMA ($199.10) as a support level.", "Consider the overall health and regulatory environment of the biotechnology sector for longer-term investment decisions.", "Given the sector concentration, be aware of the potential for higher volatility compared to broader market ETFs." ] } }, { "id": "correlations", "title": "Market Correlations", "text": [ "How this etf moves relative to other assets", "Based on 1 year of daily price data. Correlations may vary over different time periods." ], "facts": { "Correlation with S&P 500 (SPY)": "+0.59", "Correlation with Nasdaq 100 (QQQ)": "+0.50", "Correlation with Bitcoin (BTC)": "+0.05", "Correlation with Gold (XAU)": "+0.20" } }, { "id": "key-statistics", "title": "Key Statistics", "text": [ "The iShares Biotechnology ETF (IBB) has substantial net assets of $10.47 billion, indicating significant investor interest. Its expense ratio is 0.44%, which is competitive for a sector-specific ETF. The fund is heavily concentrated in the Healthcare sector, holding 99.92% in stocks, primarily within biotechnology. This concentration means its performance is closely tied to the health and innovation within the biotech industry, which is characterized by high research and development spending and regulatory scrutiny. The sector's overall performance has been mixed recently, with a YTD category return of -2.39%.", "Recent earnings reports for underlying biotechnology companies show mixed results. One report on June 22, 2026, showed an EPS actual of -0.01 against an estimate of -0.01, with a 0% surprise and a 0.62% price change. Another on May 26, 2026, had an EPS actual of -0.05 versus an estimate of -0.08, a 37.5% surprise, and a 0.27% price change. These figures suggest that while some companies are meeting or beating low expectations, the overall earnings environment for the sector may be challenging, potentially impacting IBB's performance.", "The primary risk for IBB is its high sector concentration in biotechnology, making it vulnerable to sector-specific downturns, regulatory changes, or failures in drug development pipelines. The current bearish technical indicators, including the price being below the 20-day EMA and a low RSI, suggest a heightened risk of further price declines in the short term. Additionally, the fund's performance is sensitive to broader market sentiment towards growth and innovation stocks." ], "tables": [ { "caption": "", "columns": [], "rows": [ { "label": "Net Assets (Market Cap)", "cells": [ "11.78B" ] }, { "label": "Yield", "cells": [ "0.20%" ] }, { "label": "Day High", "cells": [ "$205.31" ] }, { "label": "Day Low", "cells": [ "$202.75" ] }, { "label": "52 Week High", "cells": [ "217.12" ] }, { "label": "52 Week Low", "cells": [ "137.64" ] } ] } ] }, { "id": "technical-indicators", "title": "Technical Indicators", "text": [ "Technical Rating Bullish RSI Bearish SMA Cross Bullish Price vs SMA Bullish MACD Bullish Golden Cross in effect with the 50-day SMA ($199.10) above the 200-day SMA ($178.31), price action is firmly bullish above key moving averages." ], "facts": { "RSI": "Bearish", "SMA Cross": "Bullish", "Price vs SMA": "Bullish", "MACD": "Bullish" }, "tables": [ { "caption": "", "columns": [], "rows": [ { "label": "RSI (14)", "cells": [ "31.46" ] }, { "label": "MACD", "cells": [ "2.26" ] }, { "label": "SMA 50", "cells": [ "199.10" ] }, { "label": "SMA 200", "cells": [ "178.31" ] } ] } ] }, { "id": "trade-plans", "title": "IBB Trade Plans", "text": [ "Specific entry, exit, and risk management levels", "Lower risk, wait for rally", "Higher risk, chasing the move", "Volatility-Adjusted Stop Loss Calculated based on RSI (31.5) and current market volatility", "Consider scaling out: Take 50% profit at Target 1, 30% at Target 2, let 20% run to Target 3" ], "facts": { "TARGET 1": "$196.64", "TARGET 2": "$186.29", "TARGET 3": "$175.94", "STOP LOSS": "$213.20" } }, { "id": "seasonality", "title": "Seasonal Patterns", "text": [ "Historical monthly performance trends", "Based on 3 years of historical monthly returns" ], "facts": { "Average Jan return": "+1.66%", "Average Feb return": "-1.47%", "Average Mar return": "-2.59%", "Average Apr return": "+0.19%", "Average May return": "+0.25%", "Average Jun return": "+4.28%", "Average Jul return": "+1.77%", "Average Aug return": "+2.22%", "Average Sep return": "-1.22%", "Average Oct return": "-2.10%", "Average Nov return": "+4.31%", "Average Dec return": "-0.69%" } }, { "id": "risk", "title": "Risk & Volatility", "facts": { "Daily Volatility": "1.78%" }, "lists": { "Risk considerations": [ "Monitor position sizing based on current volatility levels", "Consider stop-loss placement beyond recent price range", "Diversification helps mitigate single-stock risk exposure" ] } }, { "id": "growth", "title": "Growth of $10,000", "text": [ "A $10,000 investment in IBB in September 2016 would be worth about $21,204 today, compared with about $35,328 for the same investment in the S&P 500 benchmark." ] }, { "id": "monte-carlo", "title": "Monte Carlo Projection (10yr)", "text": [ "CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in IBB today could grow to about $20,621 by 2036 in the base case, with a bull case near $52,845 and a bear case around $8,047. Projections are statistical simulations, not guarantees." ] }, { "id": "price-prediction", "title": "IBB ETF Price Prediction: 2030", "text": [ "CleaRank's simulation projects a price near $271 for IBB by 2030 in the base case, from $203 today (1.3x over 4 years). The downside path ends near $149. These are outcomes of a Monte Carlo simulation run on IBB's historical return distribution, not price targets, and they assume no dividends are reinvested.", "Method: 10,000 simulated price paths using IBB's historical volatility and drift, re-run daily. The base case is the median path; the two outer columns are the 10th and 90th percentile outcomes, which widen with time because uncertainty compounds. Simulations are not guarantees, and past volatility does not predict future returns. This is analysis, not investment advice." ], "tables": [ { "caption": "IBB simulated price paths by year", "columns": [ "Year", "Downside (10th pct)", "Base case", "Upside (90th pct)" ], "rows": [ { "label": "2027", "cells": [ "$162", "$218", "$294" ] }, { "label": "2028", "cells": [ "$154", "$235", "$357" ] }, { "label": "2029", "cells": [ "$151", "$252", "$422" ] }, { "label": "2030", "cells": [ "$149", "$271", "$492" ] }, { "label": "2031", "cells": [ "$150", "$291", "$567" ] }, { "label": "2032", "cells": [ "$151", "$313", "$649" ] }, { "label": "2033", "cells": [ "$153", "$337", "$740" ] }, { "label": "2034", "cells": [ "$156", "$362", "$840" ] }, { "label": "2035", "cells": [ "$159", "$389", "$950" ] }, { "label": "2036", "cells": [ "$163", "$418", "$1,072" ] } ] } ] }, { "id": "people-also-watch", "title": "People Also Watch", "links": [ { "text": "IJR iShares Core S&P Small-Cap ETF NYSE $142.19 +0.53%", "url": "https://clearank.com/etf/ijr-etf-analysis/" }, { "text": "GII State Street SPDR S&P Global Infrastructure ETF NYSE $72.83 +0.00%", "url": "https://clearank.com/etf/gii-etf-analysis/" }, { "text": "CGDV Capital Group Dividend Value ETF NYSE $49.38 +0.45%", "url": "https://clearank.com/etf/capital-group-dividend-value-cgdv/" }, { "text": "SOXQ Invesco PHLX Semiconductor ETF NASDAQ $93.11 +1.79%", "url": "https://clearank.com/etf/invesco-semiconductor-soxq/" }, { "text": "XME SPDR S&P Metals & Mining ETF NYSE $113.63 -0.99%", "url": "https://clearank.com/etf/spdr-metals-mining-xme/" }, { "text": "WIP State Street SPDR FTSE International Government Inflation-Protected Bond ETF NYSE $39.49 +0.13%", "url": "https://clearank.com/etf/wip-etf-analysis/" }, { "text": "IGV iShares Expanded Tech-Software Sector ETF CBOE $101.52 +0.32%", "url": "https://clearank.com/etf/ishares-software-igv/" }, { "text": "XLK State Street Technology Select Sector SPDR ETF NYSE $187.67 +1.32%", "url": "https://clearank.com/etf/tech-select-sector-xlk/" } ] }, { "id": "related-comparisons", "title": "Popular Comparisons", "links": [ { "text": "EQIX vs DLR Comparison Head-to-head analysis →", "url": "https://clearank.com/compare/eqix-vs-dlr/" }, { "text": "CSX vs NSC Comparison Head-to-head analysis →", "url": "https://clearank.com/compare/csx-vs-nsc/" }, { "text": "CAT vs DE Comparison Head-to-head analysis →", "url": "https://clearank.com/compare/cat-vs-de/" } ] }, { "id": "faq", "title": "Frequently Asked Questions" } ], "faq": [ { "question": "What is the expense ratio for the iShares Biotechnology ETF (IBB) and what does it cost per $10,000 invested?", "answer": "The iShares Biotechnology ETF (IBB) has an expense ratio of 0.44%. This means an investment of $10,000 would incur an annual cost of $44." }, { "question": "What sectors does the iShares Biotechnology ETF (IBB) hold and how concentrated is it?", "answer": "The iShares Biotechnology ETF (IBB) is highly concentrated in the Healthcare sector, holding 99.92% in stocks. Its portfolio focuses on U.S.-listed biotechnology companies involved in areas such as therapeutics, genetic medicine, and diagnostics." }, { "question": "What is the distribution yield for the iShares Biotechnology ETF (IBB)?", "answer": "The iShares Biotechnology ETF (IBB) has a distribution yield of 0.20%." }, { "question": "How has the iShares Biotechnology ETF (IBB) performed against its category over different timeframes?", "answer": "Over the past year, IBB returned 51.66% compared to its category's 21.31%. Over three years, IBB returned 17.87% versus the category's 6.58%. Over five years, IBB returned 4.20% compared to the category's 1.49%, and over ten years, IBB returned 8.63% against the category's 8.56%." }, { "question": "What are the nearest support and resistance levels for IBB?", "answer": "The nearest resistance for IBB is its 20-day EMA at $206.78, and the nearest support is its 50-day SMA at $199.10." }, { "question": "What is the price prediction for IBB ETF in 2030?", "answer": "Based on Monte Carlo simulations, the base case price prediction for IBB in 2030 is $271.06. The downside scenario projects a price of $149.48, while the upside scenario reaches $491.53. These are statistical simulation outcomes, not price targets or guarantees." }, { "question": "What are the key risks associated with investing in the iShares Biotechnology ETF (IBB)?", "answer": "Key risks include high sector concentration in biotechnology, vulnerability to regulatory changes and drug development failures, and sensitivity to market sentiment towards growth stocks. Current bearish technicals also indicate a short-term decline risk." } ], "related": { "peopleAlsoWatch": [ { "ticker": "IJR", "name": "iShares Core S&P Small-Cap ETF NYSE", "price": "$142.19", "change": "+0.53%", "url": "https://clearank.com/etf/ijr-etf-analysis/" }, { "ticker": "GII", "name": "State Street SPDR S&P Global Infrastructure ETF NYSE", "price": "$72.83", "change": "+0.00%", "url": "https://clearank.com/etf/gii-etf-analysis/" }, { "ticker": "CGDV", "name": "Capital Group Dividend Value ETF NYSE", "price": "$49.38", "change": "+0.45%", "url": "https://clearank.com/etf/capital-group-dividend-value-cgdv/" }, { "ticker": "SOXQ", "name": "Invesco PHLX Semiconductor ETF NASDAQ", "price": "$93.11", "change": "+1.79%", "url": "https://clearank.com/etf/invesco-semiconductor-soxq/" }, { "ticker": "XME", "name": "SPDR S&P Metals & Mining ETF NYSE", "price": "$113.63", "change": "-0.99%", "url": "https://clearank.com/etf/spdr-metals-mining-xme/" }, { "ticker": "WIP", "name": "State Street SPDR FTSE International Government Inflation-Protected Bond ETF NYSE", "price": "$39.49", "change": "+0.13%", "url": "https://clearank.com/etf/wip-etf-analysis/" }, { "ticker": "IGV", "name": "iShares Expanded Tech-Software Sector ETF CBOE", "price": "$101.52", "change": "+0.32%", "url": "https://clearank.com/etf/ishares-software-igv/" }, { "ticker": "XLK", "name": "State Street Technology Select Sector SPDR ETF NYSE", "price": "$187.67", "change": "+1.32%", "url": "https://clearank.com/etf/tech-select-sector-xlk/" } ], "comparisons": [ { "ticker": "EQIX vs DLR Comparison", "name": "", "url": "https://clearank.com/compare/eqix-vs-dlr/" }, { "ticker": "CSX vs NSC Comparison", "name": "", "url": "https://clearank.com/compare/csx-vs-nsc/" }, { "ticker": "CAT vs DE Comparison", "name": "", "url": "https://clearank.com/compare/cat-vs-de/" } ], "Newly Tracked": [ { "ticker": "AME", "text": "AMETEK, Inc.", "url": "https://clearank.com/stock/ame-stock-analysis/" }, { "ticker": "VRSK", "text": "Verisk Analytics, Inc.", "url": "https://clearank.com/stock/vrsk-stock-analysis/" }, { "ticker": "DEO", "text": "Diageo plc Sponsored", "url": "https://clearank.com/stock/deo-stock-analysis/" }, { "ticker": "KMB", "text": "Kimberly-Clark Corporation", "url": "https://clearank.com/stock/kmb-stock-analysis/" }, { "ticker": "IAUM", "text": "iShares Gold Trust Micro", "url": "https://clearank.com/etf/iaum-etf-analysis/" } ], "Top Movers (24h)": [ { "ticker": "ASPI", "text": "↓ 7.80%", "url": "https://clearank.com/stock/aspi-asp-isotopes/" }, { "ticker": "SMR", "text": "↓ 15.67%", "url": "https://clearank.com/stock/nuscale-power-smr/" }, { "ticker": "XHLD", "text": "↑ 15.04%", "url": "https://clearank.com/stock/xhld-stock-analysis/" }, { "ticker": "HPE", "text": "↑ 12.44%", "url": "https://clearank.com/stock/hewlett-packard-enterprise-hpe/" }, { "ticker": "DELL", "text": "↑ 11.98%", "url": "https://clearank.com/stock/dell-technologies-dell/" } ], "Also in Health ETFs": [ { "ticker": "IHF", "text": "iShares U.S", "url": "https://clearank.com/etf/ishares-us-healthcare-providers-ihf/" }, { "ticker": "IHI", "text": "iShares U.S", "url": "https://clearank.com/etf/ihi-etf-analysis/" }, { "ticker": "XBI", "text": "SPDR S&P Biotech", "url": "https://clearank.com/etf/spdr-biotech-xbi/" }, { "ticker": "XLV", "text": "Health Care Select Sector SPDR", "url": "https://clearank.com/etf/health-care-select-spdr-xlv/" } ] }, "schema": [ { "@context": "https://schema.org", "@graph": [ { "@type": "Place", "@id": "https://clearank.com/#place", "address": { "@type": "PostalAddress", "streetAddress": "Beni Berman 2", "addressLocality": "Netanya", "addressRegion": "Center", "postalCode": "4249330", "addressCountry": "IL" } }, { "@type": "Organization", "@id": "https://clearank.com/#organization", "name": "CleaRank", "url": "https://clearank.com", "sameAs": [ "https://twitter.com/CleaRank", "https://www.linkedin.com/company/clearank/", "https://www.youtube.com/@CleaRank" ], "email": "info@clearank.com", "address": { "@type": "PostalAddress", "streetAddress": "Beni Berman 2", "addressLocality": "Netanya", "addressRegion": "Center", "postalCode": "4249330", "addressCountry": "IL" }, "logo": { "@type": "ImageObject", "@id": "https://clearank.com/#logo", "url": "https://clearank.com/wp-content/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg", "contentUrl": "https://clearank.com/wp-content/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg", "caption": "CleaRank", "inLanguage": "en-US", "width": "336", "height": "153" }, "description": "The CleaRank vision is to bring clarity to the online trading industry and protect trader interests. We use our proprietary technology, expert analysis and verified trader insights, to deliver data driven broker evaluations you can trust. Our CLEAR™ Score is our foundation, a transparent, unbiased methodology that assesses brokers and firms based on the most critical factors including regulation, fees, platform reliability, and real user experiences. We are here to change an unfair system and unlike other review sites that are influenced by partnerships or subjective opinions, CleaRank is 100% independent–abiding by our rigorous CLEAR™ editorial code. We do not accept financial incentives from brokers, so what you see is what you get with no hidden agendas, just honest, actionable feedback. Clear data. Honest reviews. That's the CleaRank promise", "numberOfEmployees": { "@type": "QuantitativeValue", "value": "40" }, "location": { "@id": "https://clearank.com/#place" } }, { "@type": "WebSite", "@id": "https://clearank.com/#website", "url": "https://clearank.com", "name": "CleaRank", "publisher": { "@id": "https://clearank.com/#organization" }, "inLanguage": "en-US" }, { "@type": "ImageObject", "@id": "https://clearank.com/wp-content/uploads/2026/07/ishares-biotechnology-ibb.png", "url": "https://clearank.com/wp-content/uploads/2026/07/ishares-biotechnology-ibb.png", "width": "1280", "height": "720", "caption": "iShares Biotechnology ETF (IBB) ETF performance and holdings analysis for July 2026", "inLanguage": "en-US" }, { "@type": "BreadcrumbList", "@id": "https://clearank.com/etf/ishares-biotechnology-ibb/#breadcrumb", "itemListElement": [ { "@type": "ListItem", "position": "1", "item": { "@id": "https://clearank.com", "name": "Home" } }, { "@type": "ListItem", "position": "2", "item": { "@id": "https://clearank.com/etf/ishares-biotechnology-ibb/", "name": "iShares Biotechnology ETF (IBB) ETF Price Analysis" } } ] }, { "@type": "WebPage", "@id": "https://clearank.com/etf/ishares-biotechnology-ibb/#webpage", "url": "https://clearank.com/etf/ishares-biotechnology-ibb/", "name": "iShares Biotechnology ETF (IBB) ETF Forecast (2026)", "datePublished": "2026-07-03T09:44:40+00:00", "dateModified": "2026-09-12T19:56:26+00:00", "isPartOf": { "@id": "https://clearank.com/#website" }, "primaryImageOfPage": { "@id": "https://clearank.com/wp-content/uploads/2026/07/ishares-biotechnology-ibb.png" }, "inLanguage": "en-US", "breadcrumb": { "@id": "https://clearank.com/etf/ishares-biotechnology-ibb/#breadcrumb" } }, { "@type": "Organization", "@id": "https://clearank.com/writer/clearank/", "name": "CleaRank", "description": "CleaRank's vision is to bring clarity to the online trading industry and protecting trader interests by delivering data-driven broker evaluations you can trust.", "url": "https://clearank.com/writer/clearank/", "image": { "@type": "ImageObject", "@id": "https://secure.gravatar.com/avatar/4900cf75f960a22a21f1c864e98abc4d5285fa159ea1025d0e8a9db5136e28ef?s=96&d=mm&r=g", "url": "https://secure.gravatar.com/avatar/4900cf75f960a22a21f1c864e98abc4d5285fa159ea1025d0e8a9db5136e28ef?s=96&d=mm&r=g", "caption": "CleaRank", "inLanguage": "en-US" }, "sameAs": [ "https://clearank.com/", "https://twitter.com/CleaRank", "https://www.linkedin.com/company/clearank/", "https://www.youtube.com/@CleaRank" ], "worksFor": { "@id": "https://clearank.com/#organization" }, "logo": "https://clearank.com/wp-content/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg" }, { "@type": "Article", "headline": "iShares Biotechnology ETF (IBB) ETF Forecast (2026)", "datePublished": "2026-07-03T09:44:40+00:00", "dateModified": "2026-09-12T19:56:26+00:00", "author": { "@id": "https://clearank.com/writer/clearank/", "name": "CleaRank" }, "publisher": { "@id": "https://clearank.com/#organization" }, "description": "iShares Biotechnology (IBB) ETF: 0.44% expense ratio. $10.5B net assets. Health. iShares. Fund facts, AI rating, technicals and 2030 projection.", "name": "iShares Biotechnology ETF (IBB) ETF Forecast (2026)", "@id": "https://clearank.com/etf/ishares-biotechnology-ibb/#richSnippet", "isPartOf": { "@id": "https://clearank.com/etf/ishares-biotechnology-ibb/#webpage" }, "image": { "@id": "https://clearank.com/wp-content/uploads/2026/07/ishares-biotechnology-ibb.png" }, "inLanguage": "en-US", "mainEntityOfPage": { "@id": "https://clearank.com/etf/ishares-biotechnology-ibb/#webpage" } } ] }, { "@context": "https://schema.org", "@type": "FinancialProduct", "name": "iShares Biotechnology ETF (IBB)", "tickerSymbol": "IBB", "url": "https://clearank.com/etf/ishares-biotechnology-ibb/", "description": "AI-powered financial analysis for iShares Biotechnology ETF (IBB) including technical indicators, market metrics, valuation, and price targets - refreshed daily by CleaRank Financial AI.", "exchange": "NASDAQ", "offers": { "@type": "Offer", "price": 202.92999, "priceCurrency": "USD", "availability": "https://schema.org/InStock", "url": "https://clearank.com/etf/ishares-biotechnology-ibb/", "priceValidUntil": "2026-09-13" }, "provider": { "@type": "Organization", "name": "BlackRock" } }, { "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "What is the expense ratio for the iShares Biotechnology ETF (IBB) and what does it cost per $10,000 invested?", "acceptedAnswer": { "@type": "Answer", "text": "The iShares Biotechnology ETF (IBB) has an expense ratio of 0.44%. This means an investment of $10,000 would incur an annual cost of $44." } }, { "@type": "Question", "name": "What sectors does the iShares Biotechnology ETF (IBB) hold and how concentrated is it?", "acceptedAnswer": { "@type": "Answer", "text": "The iShares Biotechnology ETF (IBB) is highly concentrated in the Healthcare sector, holding 99.92% in stocks. Its portfolio focuses on U.S.-listed biotechnology companies involved in areas such as therapeutics, genetic medicine, and diagnostics." } }, { "@type": "Question", "name": "What is the distribution yield for the iShares Biotechnology ETF (IBB)?", "acceptedAnswer": { "@type": "Answer", "text": "The iShares Biotechnology ETF (IBB) has a distribution yield of 0.20%." } }, { "@type": "Question", "name": "How has the iShares Biotechnology ETF (IBB) performed against its category over different timeframes?", "acceptedAnswer": { "@type": "Answer", "text": "Over the past year, IBB returned 51.66% compared to its category's 21.31%. Over three years, IBB returned 17.87% versus the category's 6.58%. Over five years, IBB returned 4.20% compared to the category's 1.49%, and over ten years, IBB returned 8.63% against the category's 8.56%." } }, { "@type": "Question", "name": "What are the nearest support and resistance levels for IBB?", "acceptedAnswer": { "@type": "Answer", "text": "The nearest resistance for IBB is its 20-day EMA at $206.78, and the nearest support is its 50-day SMA at $199.10." } }, { "@type": "Question", "name": "What is the price prediction for IBB ETF in 2030?", "acceptedAnswer": { "@type": "Answer", "text": "Based on Monte Carlo simulations, the base case price prediction for IBB in 2030 is $271.06. The downside scenario projects a price of $149.48, while the upside scenario reaches $491.53. These are statistical simulation outcomes, not price targets or guarantees." } }, { "@type": "Question", "name": "What are the key risks associated with investing in the iShares Biotechnology ETF (IBB)?", "acceptedAnswer": { "@type": "Answer", "text": "Key risks include high sector concentration in biotechnology, vulnerability to regulatory changes and drug development failures, and sensitivity to market sentiment towards growth stocks. Current bearish technicals also indicate a short-term decline risk." } } ] } ] }